Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610909 | 0.87 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2KDM4EHPGDHTT | |
| SCHEMBL13610797 | 0.87 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2KDM4EHPGDHTT | |
| SCHEMBL12715517 | 0.83 | MAPK14 (0.53) | SMN1; SMN2MAPK14LCKLIMK1CDK2 | |
| SCHEMBL13610783 | 0.82 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2KDM4EHPGDHTT | |
| SCHEMBL9296920 | 0.80 | MAPK14 (0.51) | MAPK14LCKLIMK1TMPRSS15 | |
| SCHEMBL13543136 | 0.76 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2KDM4EHPGDHTT | |
| SCHEMBL12715569 | 0.74 | MAPK14 (0.49) | ALDH1A1SMN1; SMN2KDM4EMAPK14LCK | |
| SCHEMBL12715515 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4EHTTMAPK14 | |
| SCHEMBL12754631 | 0.72 | LIMK1 (0.50) | MAPK14LCKLIMK1 | |
| SCHEMBL13610843 | 0.72 | HCAR2 (0.44) | ALDH1A1SMN1; SMN2KDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | ALDH1A1 2368/4885SMN1; SMN2 2847/4885KDM4E 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.